Sarepta

News

PTC Therapeutics fails to convince FDA panel about DMD drug

FDA advisers have voted against approval for PTC Therapeutics’ Duchenne drug Translarna because of doubts about its efficacy.

News

FDA reviewers slam PTC's Duchenne drug ahead of meeting

FDA staff not persuaded by patchy clinical trial evidence for Translarna.

News

EU regulators reject Santhera's Raxone for DMD

Swiss company to appeal regulators' decision.

News

Sarepta announces Allergan veteran as next CEO

Sarepta has announced former Allergan president Doug Ingram will be its new CEO.

News

UK patients gain early access to Duchenne drug

Patients to get Santhera's Raxone under EAMS scheme.

News

Outrage over Duchenne drug price reinflamed by PTC's $35,000...

Families affected by the rare muscle wasting disease Duchenne muscular dystrophy will still have to pay a huge premium for Emflaza, a newly-approved drug based on an old steroid that helps

PTC Therapeutics fails to convince FDA panel about DMD drug

FDA reviewers slam PTC's Duchenne drug ahead of meeting

EU regulators reject Santhera's Raxone for DMD

Sarepta announces Allergan veteran as next CEO

UK patients gain early access to Duchenne drug

Outrage over Duchenne drug price reinflamed by PTC's $35,000...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Sarepta

Editor's Picks